John Vandermosten
@vanjohn10.bsky.social
Life Sciences, Analyst, Media Operations, Investor Awareness
Owner of Unboxing Biotech, a channel that features life sciences executives and their companies.
Owner of Unboxing Biotech, a channel that features life sciences executives and their companies.
Spectral AI reports 3Q
*$3.8mm R&D revenue
*Cash $10.5mm as of 30Sep
*$7.6mm capital raise post Q end
*Rev guidance down by $3mm to $18.5mm due to timing
$MDAI
investors.spectral-ai.com/news-release...
*$3.8mm R&D revenue
*Cash $10.5mm as of 30Sep
*$7.6mm capital raise post Q end
*Rev guidance down by $3mm to $18.5mm due to timing
$MDAI
investors.spectral-ai.com/news-release...
investors.spectral-ai.com
November 11, 2025 at 9:06 PM
Spectral AI reports 3Q
*$3.8mm R&D revenue
*Cash $10.5mm as of 30Sep
*$7.6mm capital raise post Q end
*Rev guidance down by $3mm to $18.5mm due to timing
$MDAI
investors.spectral-ai.com/news-release...
*$3.8mm R&D revenue
*Cash $10.5mm as of 30Sep
*$7.6mm capital raise post Q end
*Rev guidance down by $3mm to $18.5mm due to timing
$MDAI
investors.spectral-ai.com/news-release...
Reviva Pharmaceuticals CEO Dr. Laxminarayan Bhat, Ph.D. discusses brilaroxazine's favorable cardiac side effect profile.
youtu.be/EVDygD75wLs
#schizophrenia #biopharma #biotech $RVPH
youtu.be/EVDygD75wLs
#schizophrenia #biopharma #biotech $RVPH
Cardiac Safety Profile
YouTube video by Unboxing Biotech
youtu.be
November 11, 2025 at 2:17 PM
Reviva Pharmaceuticals CEO Dr. Laxminarayan Bhat, Ph.D. discusses brilaroxazine's favorable cardiac side effect profile.
youtu.be/EVDygD75wLs
#schizophrenia #biopharma #biotech $RVPH
youtu.be/EVDygD75wLs
#schizophrenia #biopharma #biotech $RVPH
Cingulate appoints Bryan Downey as Chief Commercial Officer to drive the product launch of CTx-1301.
$CING also completes a $6mm financing.
finance.yahoo.com/news/cingula...
$CING also completes a $6mm financing.
finance.yahoo.com/news/cingula...
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash posit...
finance.yahoo.com
November 10, 2025 at 10:06 PM
Cingulate appoints Bryan Downey as Chief Commercial Officer to drive the product launch of CTx-1301.
$CING also completes a $6mm financing.
finance.yahoo.com/news/cingula...
$CING also completes a $6mm financing.
finance.yahoo.com/news/cingula...
Reviva's brilaroxazine granted EU patent (#3749324) for treatment of pulmonary fibrosis. Builds on similar patents in US, China & Japan.
$RVPH
finance.yahoo.com/news/reviva-...
$RVPH
finance.yahoo.com/news/reviva-...
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
- Patent covers brilaroxazine use for treating Pulmonary Fibrosis -Similar patents have also been granted in key markets around the world including the United States, China, and Japan -Brilaroxazine h...
finance.yahoo.com
November 10, 2025 at 10:02 PM
Reviva's brilaroxazine granted EU patent (#3749324) for treatment of pulmonary fibrosis. Builds on similar patents in US, China & Japan.
$RVPH
finance.yahoo.com/news/reviva-...
$RVPH
finance.yahoo.com/news/reviva-...
Dyadic announces CRISPR/Cas9 licensing agreement with ERS Genomics.
Deal enhances $DYAI's ability to accelerate strain engineering & pathway optimization.
dyadic.com/dyadic-appli...
Deal enhances $DYAI's ability to accelerate strain engineering & pathway optimization.
dyadic.com/dyadic-appli...
Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics - Dyadic
JUPITER, Fla. and DUBLIN, Nov. 10, 2025 (GLOBE NEWSWIRE) — ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precisi...
dyadic.com
November 10, 2025 at 9:41 PM
Dyadic announces CRISPR/Cas9 licensing agreement with ERS Genomics.
Deal enhances $DYAI's ability to accelerate strain engineering & pathway optimization.
dyadic.com/dyadic-appli...
Deal enhances $DYAI's ability to accelerate strain engineering & pathway optimization.
dyadic.com/dyadic-appli...
Dyadic to introduce 2 products in Asia: DNase1 & human Transferrin
*Will work with Intralink Group who will conduct business development
*$DYAI will establish supply relationships
www.intralinkgroup.com/latest/news/...
*Will work with Intralink Group who will conduct business development
*$DYAI will establish supply relationships
www.intralinkgroup.com/latest/news/...
Growth in Japan and Korea for US biotech innovator
Intralink is helping Dyadic Applied BioSolutions to expand into Japan and South Korea, targeting biologics and CGT markets with innovative recombinant proteins.
www.intralinkgroup.com
November 10, 2025 at 9:35 PM
Dyadic to introduce 2 products in Asia: DNase1 & human Transferrin
*Will work with Intralink Group who will conduct business development
*$DYAI will establish supply relationships
www.intralinkgroup.com/latest/news/...
*Will work with Intralink Group who will conduct business development
*$DYAI will establish supply relationships
www.intralinkgroup.com/latest/news/...
Azitra addresses false report circulating that it had priced a $44mm offering.
$AZTR asserts that this is untrue.
The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni.
ir.azitrainc.com/news-release...
$AZTR asserts that this is untrue.
The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni.
ir.azitrainc.com/news-release...
Azitra, Inc. Addresses False Report Regarding Sale of Securities | Azitra, Inc.
BRANFORD, Conn. , Nov. 7, 2025 /PRNewswire/ -- Azitra , Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, tod...
ir.azitrainc.com
November 7, 2025 at 1:18 PM
Azitra addresses false report circulating that it had priced a $44mm offering.
$AZTR asserts that this is untrue.
The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni.
ir.azitrainc.com/news-release...
$AZTR asserts that this is untrue.
The latest capital raise we see was in January. An April announcement was made for a share purchase agreement with Alumni.
ir.azitrainc.com/news-release...
Rani Therapeutics reports 3Q
*PR reiterates recent capital raise & Chugai deal
*Plan start of RT114 trial before year end
*2 new board members
$RANI
finance.yahoo.com/news/rani-th...
*PR reiterates recent capital raise & Chugai deal
*Plan start of RT114 trial before year end
*2 new board members
$RANI
finance.yahoo.com/news/rani-th...
Rani Therapeutics (RANI) Is Up 257.9% After $1.08 Billion Chugai Deal and $60M Fundraise—What’s Changed
Rani Therapeutics Holdings recently announced a collaboration and license agreement with Chugai Pharmaceutical for the joint development and commercialization of an oral product combining Rani’s RaniP...
finance.yahoo.com
November 6, 2025 at 10:05 PM
Rani Therapeutics reports 3Q
*PR reiterates recent capital raise & Chugai deal
*Plan start of RT114 trial before year end
*2 new board members
$RANI
finance.yahoo.com/news/rani-th...
*PR reiterates recent capital raise & Chugai deal
*Plan start of RT114 trial before year end
*2 new board members
$RANI
finance.yahoo.com/news/rani-th...
It is difficult to have a conversation these days without bringing up Artificial Intelligence. Chief Commercial Officer Jaime Xinos shares how Achieve Life Sciences will use AI to improve their commercialization activities.
$ACHV
youtu.be/WzMWRekgCH8
$ACHV
youtu.be/WzMWRekgCH8
Artificial Intelligence
YouTube video by Unboxing Biotech
youtu.be
November 6, 2025 at 5:31 PM
It is difficult to have a conversation these days without bringing up Artificial Intelligence. Chief Commercial Officer Jaime Xinos shares how Achieve Life Sciences will use AI to improve their commercialization activities.
$ACHV
youtu.be/WzMWRekgCH8
$ACHV
youtu.be/WzMWRekgCH8
Achieve Life Sciences reports 3Q.
Reiterates
*20Jun26 PDUFA
*New legal officer
*Thorax publication
*Vaping priority voucher
*All safety data submitted
*Call @ 8:30 am ET
$ACHV
achievelifesciences.com/achieve-anno...
Reiterates
*20Jun26 PDUFA
*New legal officer
*Thorax publication
*Vaping priority voucher
*All safety data submitted
*Call @ 8:30 am ET
$ACHV
achievelifesciences.com/achieve-anno...
Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program - Achieve Life Sciences
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping Cessation Conference Call Scheduled for 8:30 AM EST Today, November 6, 2025 S...
achievelifesciences.com
November 6, 2025 at 12:25 PM
Achieve Life Sciences reports 3Q.
Reiterates
*20Jun26 PDUFA
*New legal officer
*Thorax publication
*Vaping priority voucher
*All safety data submitted
*Call @ 8:30 am ET
$ACHV
achievelifesciences.com/achieve-anno...
Reiterates
*20Jun26 PDUFA
*New legal officer
*Thorax publication
*Vaping priority voucher
*All safety data submitted
*Call @ 8:30 am ET
$ACHV
achievelifesciences.com/achieve-anno...
Ligand Pharmaceuticals reports 3Q
*Revs of $115mm vs $59mm, beat due to $PTHS
*Core adj EPS of $3.09 vs $1.91
*EPS & Rev guidance up
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...
*Revs of $115mm vs $59mm, beat due to $PTHS
*Core adj EPS of $3.09 vs $1.91
*EPS & Rev guidance up
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...
Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance
Third quarter performance driven by strong portfolio royalty revenue growth of 47% 2025 full year revenue guidance increased to $225 million - $235 million (previously $200 million - $225 million) and...
investor.ligand.com
November 6, 2025 at 12:20 PM
Ligand Pharmaceuticals reports 3Q
*Revs of $115mm vs $59mm, beat due to $PTHS
*Core adj EPS of $3.09 vs $1.91
*EPS & Rev guidance up
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...
*Revs of $115mm vs $59mm, beat due to $PTHS
*Core adj EPS of $3.09 vs $1.91
*EPS & Rev guidance up
*Call @ 8:30 am ET
$LGND
investor.ligand.com/news-and-eve...
Lantheus reports 3Q
*Revs of $384mm vs our $361mm
*adj EPS of $1.27 vs our $1.16
*CEO to retire
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...
*Revs of $384mm vs our $361mm
*adj EPS of $1.27 vs our $1.16
*CEO to retire
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...
lantheusholdings.gcs-web.com
November 6, 2025 at 12:11 PM
Lantheus reports 3Q
*Revs of $384mm vs our $361mm
*adj EPS of $1.27 vs our $1.16
*CEO to retire
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...
*Revs of $384mm vs our $361mm
*adj EPS of $1.27 vs our $1.16
*CEO to retire
*Call @ 8 am ET
$LNTH
lantheusholdings.gcs-web.com/news-release...
Why is drug half life important & how does this impact the # of CTx-1301 doses needed? The principal investigator for Cingulate Inc.'s trials, Dr. Ann Childress, explains how #ADHD medicines' half life can let symptoms return in the evening.
$CING
youtu.be/pp-zEKCkjGM
$CING
youtu.be/pp-zEKCkjGM
Importance of Drug Half Life
YouTube video by Unboxing Biotech
youtu.be
November 5, 2025 at 7:30 PM
Why is drug half life important & how does this impact the # of CTx-1301 doses needed? The principal investigator for Cingulate Inc.'s trials, Dr. Ann Childress, explains how #ADHD medicines' half life can let symptoms return in the evening.
$CING
youtu.be/pp-zEKCkjGM
$CING
youtu.be/pp-zEKCkjGM
GeoVax to report 3Q on 13Nov.
*Call @ 4:30 pm ET
*Details provided in PR
$GOVX
finance.yahoo.com/news/geovax-...
*Call @ 4:30 pm ET
*Details provided in PR
$GOVX
finance.yahoo.com/news/geovax-...
GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
ATLANTA, GA - November 4, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases a...
finance.yahoo.com
November 5, 2025 at 1:44 PM
GeoVax to report 3Q on 13Nov.
*Call @ 4:30 pm ET
*Details provided in PR
$GOVX
finance.yahoo.com/news/geovax-...
*Call @ 4:30 pm ET
*Details provided in PR
$GOVX
finance.yahoo.com/news/geovax-...
Reviva's Dr Bhat identifies the benefits of obtaining an FDA approval for brilaroxazine targeting the negative symptoms of schizophrenia.
$RVPH
youtu.be/JqAbGKkCh8k
#schizophrenia #biopharma #biotech
$RVPH
youtu.be/JqAbGKkCh8k
#schizophrenia #biopharma #biotech
Negative Symptoms
YouTube video by Unboxing Biotech
youtu.be
November 4, 2025 at 2:26 PM
Reviva's Dr Bhat identifies the benefits of obtaining an FDA approval for brilaroxazine targeting the negative symptoms of schizophrenia.
$RVPH
youtu.be/JqAbGKkCh8k
#schizophrenia #biopharma #biotech
$RVPH
youtu.be/JqAbGKkCh8k
#schizophrenia #biopharma #biotech
Protalix & Chiesi request a re-examination of the negative opinion given by the CHMP of the EMA regarding Elfabrio's dosing modification from 2 to 4 weeks.
2 week dosing remains the standard pending the outcome.
$PLX
finance.yahoo.com/news/chiesi-...
2 week dosing remains the standard pending the outcome.
$PLX
finance.yahoo.com/news/chiesi-...
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in...
-- Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the ...
finance.yahoo.com
November 4, 2025 at 12:25 PM
Protalix & Chiesi request a re-examination of the negative opinion given by the CHMP of the EMA regarding Elfabrio's dosing modification from 2 to 4 weeks.
2 week dosing remains the standard pending the outcome.
$PLX
finance.yahoo.com/news/chiesi-...
2 week dosing remains the standard pending the outcome.
$PLX
finance.yahoo.com/news/chiesi-...
TuHURA Biosciences presentation picked for ASH Meeting
*Delta Opioid Receptor (DOR) Expression on Myeloid-Derived Suppressor Cells (MDSCs) Represents a Novel Target to Overcome Resistance to Immune Checkpoint Inhibitors (ICIs)
*7Dec
*Orlando FL
$HURA
finance.yahoo.com/news/tuhura-...
*Delta Opioid Receptor (DOR) Expression on Myeloid-Derived Suppressor Cells (MDSCs) Represents a Novel Target to Overcome Resistance to Immune Checkpoint Inhibitors (ICIs)
*7Dec
*Orlando FL
$HURA
finance.yahoo.com/news/tuhura-...
TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting a...
TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its research on...
finance.yahoo.com
November 3, 2025 at 3:57 PM
TuHURA Biosciences presentation picked for ASH Meeting
*Delta Opioid Receptor (DOR) Expression on Myeloid-Derived Suppressor Cells (MDSCs) Represents a Novel Target to Overcome Resistance to Immune Checkpoint Inhibitors (ICIs)
*7Dec
*Orlando FL
$HURA
finance.yahoo.com/news/tuhura-...
*Delta Opioid Receptor (DOR) Expression on Myeloid-Derived Suppressor Cells (MDSCs) Represents a Novel Target to Overcome Resistance to Immune Checkpoint Inhibitors (ICIs)
*7Dec
*Orlando FL
$HURA
finance.yahoo.com/news/tuhura-...
GeoVax to relocate HQ to Portal Atlanta @ Science Square Labs, close to other development life sciences companies, modern labs & collaborative research environments.
$GOVX
finance.yahoo.com/news/geovax-...
$GOVX
finance.yahoo.com/news/geovax-...
GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
Relocations Strengthen Ties to Georgia's Bio-Ecosystem and Position GeoVax for Late-Stage Development and Market Readiness ATLANTA, GA - November 3, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GO...
finance.yahoo.com
November 3, 2025 at 3:53 PM
GeoVax to relocate HQ to Portal Atlanta @ Science Square Labs, close to other development life sciences companies, modern labs & collaborative research environments.
$GOVX
finance.yahoo.com/news/geovax-...
$GOVX
finance.yahoo.com/news/geovax-...
Achieve Life Sciences submits its ORCA-OL 1 year exposure data to FDA
*Participants:
~411-six months
~214-twelve months
*DSMC-no safety concerns
Here's CEO Rick Stewart talking milestones:
youtu.be/YkqxjZSkbrI
$ACHV PR: finance.yahoo.com/news/achieve...
*Participants:
~411-six months
~214-twelve months
*DSMC-no safety concerns
Here's CEO Rick Stewart talking milestones:
youtu.be/YkqxjZSkbrI
$ACHV PR: finance.yahoo.com/news/achieve...
Achieve Near Term Milestones
YouTube video by Unboxing Biotech
youtu.be
November 3, 2025 at 3:47 PM
Achieve Life Sciences submits its ORCA-OL 1 year exposure data to FDA
*Participants:
~411-six months
~214-twelve months
*DSMC-no safety concerns
Here's CEO Rick Stewart talking milestones:
youtu.be/YkqxjZSkbrI
$ACHV PR: finance.yahoo.com/news/achieve...
*Participants:
~411-six months
~214-twelve months
*DSMC-no safety concerns
Here's CEO Rick Stewart talking milestones:
youtu.be/YkqxjZSkbrI
$ACHV PR: finance.yahoo.com/news/achieve...
Get ready for Achieve Life Sciences' 3Q report on Thursday morning with a review of $ACHV balance sheet. CEO Rick Stewart talks about capital efficiency, how long funds will last and new sources of capital that look attractive.
youtu.be/yn4trf9gpKA
youtu.be/yn4trf9gpKA
Achieve Balance Sheet
YouTube video by Unboxing Biotech
youtu.be
November 3, 2025 at 1:00 PM
Get ready for Achieve Life Sciences' 3Q report on Thursday morning with a review of $ACHV balance sheet. CEO Rick Stewart talks about capital efficiency, how long funds will last and new sources of capital that look attractive.
youtu.be/yn4trf9gpKA
youtu.be/yn4trf9gpKA
GeoVax highlights its Ph2 COVID vaccine data in the context of IDSA guidance on prioritizing vaccination for immunocompromised individuals.
$GOVX presented this data @ the World Vaccine Congress Europe showing Tcell responses, cross variant immunity & safety.
finance.yahoo.com/news/geovax-...
$GOVX presented this data @ the World Vaccine Congress Europe showing Tcell responses, cross variant immunity & safety.
finance.yahoo.com/news/geovax-...
GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1
IDSA's Recommendations Reinforce GeoVax's Phase 2 Findings: Robust T-Cell Responses, Cross-Variant Durability, and Favorable Safety Profile in Vulnerable Populations ATLANTA, GA - October 29, 2025 (NE...
finance.yahoo.com
October 31, 2025 at 2:16 PM
GeoVax highlights its Ph2 COVID vaccine data in the context of IDSA guidance on prioritizing vaccination for immunocompromised individuals.
$GOVX presented this data @ the World Vaccine Congress Europe showing Tcell responses, cross variant immunity & safety.
finance.yahoo.com/news/geovax-...
$GOVX presented this data @ the World Vaccine Congress Europe showing Tcell responses, cross variant immunity & safety.
finance.yahoo.com/news/geovax-...
Achieve Life Sciences to report 3Q on 6Nov.
Call @ 8:30 am CT
Get up to speed with an update on milestones:
youtu.be/YkqxjZSkbrI
$ACHV
finance.yahoo.com/news/achieve...
Call @ 8:30 am CT
Get up to speed with an update on milestones:
youtu.be/YkqxjZSkbrI
$ACHV
finance.yahoo.com/news/achieve...
Achieve Near Term Milestones
YouTube video by Unboxing Biotech
youtu.be
October 29, 2025 at 1:00 PM
Achieve Life Sciences to report 3Q on 6Nov.
Call @ 8:30 am CT
Get up to speed with an update on milestones:
youtu.be/YkqxjZSkbrI
$ACHV
finance.yahoo.com/news/achieve...
Call @ 8:30 am CT
Get up to speed with an update on milestones:
youtu.be/YkqxjZSkbrI
$ACHV
finance.yahoo.com/news/achieve...
Reviva Pharmaceuticals will attend the Spartan Capital Securities conference 3Nov.
To get you warmed up, here's Dr Bhat discussing Neuroinflammation:
youtu.be/rm1bLPbi8FE
$RVPH
finance.yahoo.com/news/reviva-...
To get you warmed up, here's Dr Bhat discussing Neuroinflammation:
youtu.be/rm1bLPbi8FE
$RVPH
finance.yahoo.com/news/reviva-...
Neuroinflammation
YouTube video by Unboxing Biotech
youtu.be
October 29, 2025 at 12:48 PM
Reviva Pharmaceuticals will attend the Spartan Capital Securities conference 3Nov.
To get you warmed up, here's Dr Bhat discussing Neuroinflammation:
youtu.be/rm1bLPbi8FE
$RVPH
finance.yahoo.com/news/reviva-...
To get you warmed up, here's Dr Bhat discussing Neuroinflammation:
youtu.be/rm1bLPbi8FE
$RVPH
finance.yahoo.com/news/reviva-...
Dyadic Applied Biosolutions to report 3Q 12Nov.
Call @ 5 pm ET.
$DYAI
finance.yahoo.com/news/dyadic-...
Call @ 5 pm ET.
$DYAI
finance.yahoo.com/news/dyadic-...
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
JUPITER, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology com...
finance.yahoo.com
October 29, 2025 at 12:45 PM
Dyadic Applied Biosolutions to report 3Q 12Nov.
Call @ 5 pm ET.
$DYAI
finance.yahoo.com/news/dyadic-...
Call @ 5 pm ET.
$DYAI
finance.yahoo.com/news/dyadic-...
